Health Vidya

To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin capsules, USP and other antibacterial drugs, amoxicillin capsules, USP should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin capsules, USP are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of the designated bacteria in the conditions listed below: Due to species (α- and β-hemolytic isolates only), , spp., or . Streptococcus Streptococcus pneumoniae Staphylococcus Haemophilus influenzae Due to , or . Escherichia coli, Proteus mirabilis Enterococcus faecalis Due to spp. (α- and β-hemolytic isolates only), spp., or . Streptococcus Staphylococcus E. coli Due to spp. (α- and β-hemolytic isolates only), spp., or . Streptococcus S. pneumoniae, Staphylococcus H. influenzae Due to . Because of high rates of amoxicillin resistance, amoxicillin capsules, USP are not recommended for empiric treatment of gonorrhea. Amoxicillin capsules, USP use should be limited to situations where isolates are known to be susceptible to amoxicillin. Neisseria gonorrhoeae N. gonorrhoeae Amoxicillin capsules, USP, in combination with clarithromycin plus lansoprazole as triple therapy, are indicated for the treatment of patients with infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate . Eradication of has been shown to reduce the risk of duodenal ulcer recurrence. H. pylori H. pylori H. pylori Amoxicillin capsules, USP, in combination with lansoprazole delayed-release capsules as dual therapy, are indicated for the treatment of patients with infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) . (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of has been shown to reduce the risk of duodenal ulcer recurrence. H. pylori who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected H. pylori